Search / Trial NCT00002432

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Launched by ASTRA USA · Aug 30, 2001

Trial Information

Current as of January 03, 2025

Completed

Keywords

Retinitis Aids Related Opportunistic Infections Foscarnet Cytomegalovirus Infections Acquired Immunodeficiency Syndrome

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Prior Medication:
  • Allowed:
  • Ganciclovir (DHPG).
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following are excluded:
  • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
  • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic, and/or hypertensive retinopathy.
  • Known allergy to foscarnet.
  • Concurrent Medication:
  • Excluded:
  • Nephrotoxic drugs.
  • Acyclovir.
  • Patients with the following are excluded:
  • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
  • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic, and/or hypertensive retinopathy.
  • Known allergy to foscarnet.
  • Prior Medication:
  • Excluded within 7 days of study entry:
  • Immunomodulators.
  • Biologic response modifiers.
  • Investigational agents (other than ganciclovir).
  • Patients with AIDS as defined by the CDC, with manifest first episode cytomegalovirus (CMV) retinitis as identified by its characteristic ophthalmoscopic appearance and verified by fundus photography.
  • Patients must be able to give informed consent.
  • * Patients who enter the study because of ganciclovir toxicity will have received ganciclovir therapy which resulted in either absolute neutrophil count falling to \< 750 cells/mm3 or platelet count falling to \< 50000 platelets/mm3 on two separate occasions during either:
  • A ganciclovir induction regimen of 7.5 mg (or more)/kg/day in divided doses.
  • A maintenance regimen of 5 mg (or more)/kg/day as a single daily dose.
  • * Patients who enter the study because of ganciclovir treatment failure will meet one of the following criteria:
  • CMV retinitis progression has occurred either 1) at the end of a 10 - 21 day induction course of ganciclovir (7.5 - 10 mg/kg/day in divided doses) or 2) during the first 28 days of maintenance ganciclovir therapy (5 mg (or more)/kg/day, at least 5 days/week) where maintenance therapy began within 1 week of completing induction therapy.

About Astra Usa

Astra USA, a subsidiary of AstraZeneca, is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines that address unmet medical needs across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. With a strong commitment to advancing healthcare, Astra USA leverages cutting-edge science and technology to deliver high-quality treatments and improve patient outcomes. The organization emphasizes collaboration with healthcare professionals, regulatory bodies, and patient communities to ensure the safety and efficacy of its clinical trials, ultimately striving to enhance the quality of life for patients globally.

Locations

San Francisco, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials